Cumulative Genetic Burden Defines a Gradient of Risk in MYBPC3 -Related Hypertrophic Cardiomyopathy

BACKGROUND: MYBPC3 truncating variants ( MYBPC3tv ) represent the most common genetic substrate in hypertrophic cardiomyopathy, yet carriers show substantial phenotypic variability despite a shared mechanism of haploinsufficiency. The contribution of additional genetic variants to this variability remains incompletely defined. METHODS: We analyzed 11 991 unrelated hypertrophic cardiomyopathy probands undergoing clinical genetic testing. Analyses focused on MYBPC3tv carriers stratified by additional intermediate-effect variants (IEVs) or second monogenic variants. IEVs were further classified as sarcomeric or nonsarcomeric. All probands were genetically characterized at a single center using standardized sequencing protocols, with uniform ascertainment of IEVs throughout the study period. Primary outcomes included age-related penetrance, maximal left ventricular wall thickness, and major adverse cardiovascular events; independent predictors were assessed by a multivariable Cox regression model. RESULTS: Among 2767 genotype-positive probands, MYBPC3 accounted for 47.6% of cases, with truncating variants representing 81.9% of MYBPC3 -positive individuals. Within MYBPC3tv carriers, additional variants were associated with a stepwise gradient of disease severity. Median age at diagnosis decreased from 48 years in isolated carriers to 42 years in MYBPC3tv +IEV and 28 years in double-monogenic carriers, whereas mean wall thickness increased from 21.3 to 24.1 and 26.3 mm, respectively. In multivariable analyses, cumulative genetic burden remained an independent predictor of major adverse cardiovascular event. Sarcomeric IEV carriers (hazard ratio, 10.3 [95% CI, 2.3–28.7]) and biallelic MYBPC3 carriers (hazard ratio, 23.2 [95% CI, 5.3–115.0]) exhibited the highest risk, although estimates in these subgroups should be interpreted cautiously given the limited number of events. All biallelic MYBPC3 carriers were diagnosed in childhood. CONCLUSIONS: Cumulative rare variant burden explains a subset of the phenotypic heterogeneity among MYBPC3tv carriers, defining a hierarchical gradient of disease expression. Intermediate-effect alleles and second monogenic variants, particularly biallelic MYBPC3 , identify higher-risk subgroups that may benefit from intensified surveillance, individualized management, and guided therapies.

Authors

Institutions

Publication Details

Journal
Circulation Genomic and Precision Medicine
Published
2026-11-12
DOI
https://doi.org/10.1161/circgen.126.005754
Primary Topic
Cardiomyopathy and Myosin Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cumulative Genetic Burden Defines a Gradient of Risk in MYBPC3 -Related Hypertrophic Cardiomyopathy

Fatbardha Varfaj, Roberto Barriales‐Villa, Nerea Mora Ayestarán, William John McKenna et al.
Circulation Genomic and Precision Medicine
Cardiomyopathy and Myosin Studies
article

Cumulative Genetic Burden Defines a Gradient of Risk in MYBPC3 -Related Hypertrophic Cardiomyopathy

Fatbardha Varfaj, Roberto Barriales‐Villa, Nerea Mora Ayestarán, William John McKenna, Susana Martínez Huertas, Xusto Fernández, Juan Ramón Gimeno, Jesús Piqueras‐Flores, María Valverde-Gómez, María Gallego‐Delgado, Ana García Ruano, Maria Noël Brögger, José María Larrañaga-Moreira, Natalia Sonicheva‐Paterson, Roddy Walsh, Pablo García‐Pavía, Ivonne Johana Cárdenas Reyes, Juan Pablo Ochoa, Almudena Amor‐Salamanca, María Teresa Basurte-Elorz, Adrián Fernández, Soledad García-Hernández, Luis de la Higuera Romero, Perry M Elliot, Whittemore G. Tingley, María Luisa Peña‐Peña, Mattew J. Pollman
article en

Abstract

BACKGROUND: MYBPC3 truncating variants ( MYBPC3tv ) represent the most common genetic substrate in hypertrophic cardiomyopathy, yet carriers show substantial phenotypic variability despite a shared mechanism of haploinsufficiency. The contribution of additional genetic variants to this variability remains incompletely defined. METHODS: We analyzed 11 991 unrelated hypertrophic cardiomyopathy probands undergoing clinical genetic testing. Analyses focused on MYBPC3tv carriers stratified by additional intermediate-effect variants (IEVs) or second monogenic variants. IEVs were further classified as sarcomeric or nonsarcomeric. All probands were genetically characterized at a single center using standardized sequencing protocols, with uniform ascertainment of IEVs throughout the study period. Primary outcomes included age-related penetrance, maximal left ventricular wall thickness, and major adverse cardiovascular events; independent predictors were assessed by a multivariable Cox regression model. RESULTS: Among 2767 genotype-positive probands, MYBPC3 accounted for 47.6% of cases, with truncating variants representing 81.9% of MYBPC3 -positive individuals. Within MYBPC3tv carriers, additional variants were associated with a stepwise gradient of disease severity. Median age at diagnosis decreased from 48 years in isolated carriers to 42 years in MYBPC3tv +IEV and 28 years in double-monogenic carriers, whereas mean wall thickness increased from 21.3 to 24.1 and 26.3 mm, respectively. In multivariable analyses, cumulative genetic burden remained an independent predictor of major adverse cardiovascular event. Sarcomeric IEV carriers (hazard ratio, 10.3 [95% CI, 2.3–28.7]) and biallelic MYBPC3 carriers (hazard ratio, 23.2 [95% CI, 5.3–115.0]) exhibited the highest risk, although estimates in these subgroups should be interpreted cautiously given the limited number of events. All biallelic MYBPC3 carriers were diagnosed in childhood. CONCLUSIONS: Cumulative rare variant burden explains a subset of the phenotypic heterogeneity among MYBPC3tv carriers, defining a hierarchical gradient of disease expression. Intermediate-effect alleles and second monogenic variants, particularly biallelic MYBPC3 , identify higher-risk subgroups that may benefit from intensified surveillance, individualized management, and guided therapies.

Circulation Genomic and Precision Medicine
Universidade da Coruña (ES), St Bartholomew's Hospital (GB), Spanish National Centre for Cardiovascular Research (ES), British Heart Foundation (GB), Centro de Investigación en Red en Enfermedades Cardiovasculares (ES), Complejo Hospitalario de Salamanca (ES), Hospital Universitario 12 De Octubre (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Instituto de Investigación Biosanitaria de Granada (ES), Hospital General Universitario de Ciudad Real (ES), Complejo Hospitalario de Jaén (ES), Fundacion Favaloro Hospital Universitario (AR), Spanish National Centre for Cardiovascular Research (ES), Clinica Universidad de Navarra (ES), Complexo Hospitalario Universitario A Coruña (ES), Hospital Universitario Virgen de la Arrixaca (ES), Hospital Universitario Virgen del Rocío (ES), Favaloro Foundation (AR), Instituto de Investigación Biomédica de A Coruña (ES), City St George's, University of London (GB), University College London (GB), University of Castilla-La Mancha (ES)
Good health and well-being
Cardiomyopathy and Myosin Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon